Switzerland becomes the 14th country where patients can access Tilray medical cannabis products
NANAIMO, British Columbia--(BUSINESS WIRE)-- Tilray, Inc. (“Tilray” or “the Company”) (NASDAQ: TLRY), a global leader in medical cannabis research, cultivation, production and distribution, today announced it has successfully exported medical cannabis extracts to Switzerland. Tilray’s entry into Switzerland marks the fourteenth country to distribute Tilray’s medical cannabis products, from its Good Manufacturing Practices (GMP)-certified production facility, to patients in need.
“We’re proud to deliver Tilray’s medical cannabis to Swiss patients in need as we continue our expansion into Europe and around the globe,” says Sascha Mielcarek, Tilray’s Managing Director in Europe. “Tilray is committed to quality and patient safety and we look forward to significantly improving the quality of lives of Swiss patients through our medical cannabis products.”
The import and export permits were received in early December 2019, with the shipment of Tilray’s medical cannabis extracts successfully arriving in Switzerland on December 13. Following this first shipment of extracts, Tilray also anticipates exporting dried medical cannabis to Switzerland, offering patients an assortment of form factors to meet their varying medical indications.
Last week, Tilray announced it received an additional GMP certification for its EU campus in Portugal, allowing the site to supply medical cannabis products to international patients, partners and markets. Tilray expects to supply its European partners from its EU campus in Cantanhede, Portugal beginning 2020.
About Tilray® Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 14 countries spanning five continents.
Cautionary note regarding forward-looking statements:
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements or forward-looking-information in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking statements are not a guarantee of future performance, future action or any particular result to clinical trials, and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future medical and adult-use cannabis regulatory environment, medical cannabis demand and market structure and future approvals and permits. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the U.S. Securities and Exchange Commission and Canadian securities regulators on November 13, 2019, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Tilray does not undertake and specifically declines any obligation to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
Source: Tilray, Inc.